| Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review M Antoniou, AL Jorgensen, R Kolamunnage-Dona PLoS ONE 11 (2), e0149803, 2016 | 98 | 2016 |
| Biomarker-guided trials: challenges in practice M Antoniou, R Kolamunnage-Dona, J Wason, R Bathia, C Billingham, ... Contemporary Clinical Trials Communications 16, 100493, 2019 | 38 | 2019 |
| Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review M Antoniou, R Kolamunnage-Dona, AL Jorgensen Journal of Personalized Medicine 7 (1), 2017 | 38 | 2017 |
| Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications MG Krebs, JY Blay, C Le Tourneau, D Hong, L Veronese, M Antoniou, ... ESMO open 6 (2), 100072, 2021 | 18 | 2021 |
| Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer P Chu, M Antoniou, MK Bhutani, A Aziez, M Daigl Journal of Comparative Effectiveness Research 9 (15), 861-876, 2020 | 9 | 2020 |
| A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER” S Ogale, CEH Zerbini, M Antoniou, R Freund Journal of Managed Care & Specialty Pharmacy 26 (12), 1616-1617, 2020 | 3 | 2020 |
| Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1 M Antoniou, R Kolamunnage-Dona, AL Jorgensen Journal of Personalized Medicine 8 (2), 17, 2018 | 2 | 2018 |
| Fixed and adaptive parallel subgroup-specific design for survival outcomes: power and sample size M Antoniou, AL Jorgensen, R Kolamunnage-Dona Journal of Personalized Medicine 7 (4), 19, 2017 | 2 | 2017 |
| PRO41 The Economic and Quality of Life impact of Entrectinib on CNS metastasis control D Tan, M Antoniou, CH Zerbini Value in Health 24, S204-S205, 2021 | 1 | 2021 |
| SA83 {Maicplus}: An R Package to Support Analysis and Reporting of Matching Adjusted Indirect Treatment Comparisons (MAIC) for HTA Dossiers G Chen, M Seo, M Antoniou, R Belleli, C Kalyvas, I Gravestock Value in Health 26 (12), S558, 2023 | | 2023 |
| Biomarker-Guided Trials LC Brown, AL Jorgensen, M Antoniou, J Wason Principles and Practice of Clinical Trials, 1-26, 2022 | | 2022 |
| PCN18 Matching-Adjusted Indirect Comparison (MAIC) of Entrectinib Versus Crizotinib in Patients with ROS1 NON-SMALL CELL LUNG Cancer (NSCLC): An Updated Analysis P Chu, CR Mitchell, S Batson, A Aziez, M Antoniou Value in Health 23, S423-S424, 2020 | | 2020 |
| MATCHING-ADJUSTED INDIRECT COMPARISON OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS P Chu, M Antoniou, MK Bhutani, A Aziez, M Daigl ISPOR Europe 2019, 2019 | | 2019 |
| PCN14 MATCHING-ADJUSTED INDIRECT COMPARISON OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS P Chu, M Antoniou, MK Bhutani, A Aziez, M Daigl Value in Health 22, S437, 2019 | | 2019 |
| Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7, 19 M Antoniou, AL Jorgensen, R Kolamunnage-Dona Journal of Personalized Medicine 8 (2), 18, 2018 | | 2018 |
| Biomarker-Guided Clinical Trial Designs M Antoniou PQDT-Global, 2018 | | 2018 |
| Biomarker-guided clinical trial designs: sample size calculations with survival endpoints M Antoniou, R Kolamunnage-Dona, AL Jorgensen TRIALS 18, 2017 | | 2017 |
| Evaluating statistical characteristics of biomarker-guided trial designs M Antoniou, A Jorgensen, R Kolamunnage-Dona Trials 16 (Suppl 2), O83, 2015 | | 2015 |
